We serve Chemical Name:1-(2-piperidin-4-ylethyl)pyrrolidin-2-one CAS:763908-64-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1-(2-piperidin-4-ylethyl)pyrrolidin-2-one
CAS.NO:763908-64-1
Synonyms:1-(2-piperidin-4-ylethyl)pyrrolidin-2-one
Molecular Formula:C11H20N2O
Molecular Weight:196.28900
HS Code:2933790090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:348.5ºC at 760 mmHg
Density:1.02g/cm3
Index of Refraction:1.492
PSA:32.34000
Exact Mass:196.15800
LogP:1.26520
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like 1-(2-piperidin-4-ylethyl)pyrrolidin-2-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-(2-piperidin-4-ylethyl)pyrrolidin-2-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-(2-piperidin-4-ylethyl)pyrrolidin-2-one Use and application,1-(2-piperidin-4-ylethyl)pyrrolidin-2-one technical grade,usp/ep/jp grade.
Related News: European companies are the main suppliers of specialty APIs, but due to environmental and cost pressures, APIs have begun to shift to the Asian market. 1-(2-piperidin-4-ylethyl)pyrrolidin-2-one manufacturer The target screening performed by Retrogenix will focus on hundreds of novel, prioritized antibodies in Resonant��s collection. 1-(2-piperidin-4-ylethyl)pyrrolidin-2-one supplier European companies are the main suppliers of specialty APIs, but due to environmental and cost pressures, APIs have begun to shift to the Asian market. 1-(2-piperidin-4-ylethyl)pyrrolidin-2-one vendor The target screening performed by Retrogenix will focus on hundreds of novel, prioritized antibodies in Resonant��s collection. 1-(2-piperidin-4-ylethyl)pyrrolidin-2-one factory The FDA has granted so-called accelerated approval in more than 250 instances since 1992, mainly for rare diseases or small patient populations that have had no effective treatments available to them. In these cases, the agency requires that drugmakers conduct additional clinical trials to prove their therapy works, or face withdrawal from the market.
